antitumor agent

Antitumor agent-2 has anti-inflammatory and anti-tumor activity and can be used to study cancer.

Antitumor agent-19 is a modulator of tumor-associated macrophages with EC50s of 17.18 μM and 18.87 μM in the RAW 264.7 cells and the BMDM cells.

(2E)-3-(3,5-dimethoxyphenyl)-1-(2-methoxyphenyl)prop-2-en-1-one is also known as DMPVP.It is a novel synthetic compound belonging to the class of cathinones that is psychoactive.

2-({[2-(4-ethoxy-3-methoxyphenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)pyrimidine-4,6-diamine can be used in the development of new deoxycytidine kinase (dCK) inhibitors.

Antitumor agent-87 is an antitumor agent with antiproliferative activity that induces cell cycle arrest.

Antitumor agent-93 (compound 7D) effectively inhibits the proliferation of multiple tumor cell lines, including MDA-MB-231 and HCT-116 [1].

Antitumor agent-120 (compound 1), a flavonoid derived from Kudzu root, exhibits negligible inhibitory effects on LNCaP and PC3 cancer cells, with IC50 values exceeding 50 μM [1].

Antitumor agent-89 (Compd OTS-5), a naturally occurring compound, exhibits weak inhibitory activity against fMLP-induced superoxide generation [1].

Antitumor Agent-106 (Compound 42) is a potent anticancer compound, demonstrating significant inhibitory activity (IC50 = 4.2-6.6 µM) against lung and colon cancer cell lines [1].

Antitumor agent-67 (compound 3), a potent antitumor agent, exhibits highly selective toxicity toward cancer cells while sparing normal cells. This compound can be activated by NQO1 to effectively release podophyllotoxin, thereby killing tumor cells. In HepG2 xenograft models, Antitumor agent-67 significantly inhibits cancer growth with minimal toxicity [1].

Antitumor agent-119 (compound 13K), a 2-benzoxazolyl hydrazone derivative, exhibits anticancer capabilities by impeding the proliferation of Burkitt, CCRF-CEM, HeLa, and HT-29 cells, with respective IC50 values of 30 nM, 140 nM, 100 nM, and 40 nM [1].

Antitumor Agent-105 (Compound 37) exhibits antitumor activity, demonstrating inhibition of A549, H1299, H460, HCT116, and MDA-MB-231 cells with respective IC50 values of 6.7, 8.3, 4.3, 4.4, and 6.7 μM [1].

Antitumor agent-49 (Compound 10), a harmine derivative-furoxan hybrid featuring nitric oxide (NO) donating properties, exhibits cytotoxic effects against HepG2 cells, achieving an IC50 value of 1.79 µM and inducing significant NO production in vitro [1].

Antitumor Agent-40 serves as a research chemical for investigating cancer [1].

Antitumor agent-29 is a hepatocyte-targeting prodrug with demonstrated efficacy and minimal toxicity in anticancer applications.

Antitumor agent-107 (compound 5h) is an anticancer agent that exhibits potent inhibitory activity against leukemia cell lines (GI 50 =0.32-1.34 μM), and demonstrates broad-spectrum antitumor effects across a range of other human cancer cell lines (GI 50 =0.35-9.43 μM) [1].

Antitumor Agent-39 is a peptide-based compound with anticancer properties[1].

Antitumor agent-62 is an NO-releasing antitumor agent that exhibits antiproliferative effects on cancer cells, activates the mitochondrial apoptosis pathway, and is capable of blocking the cell cycle to G2/M phase.

Antitumor agent-112 (compound 3a) is a potent antitumor agent that induces apoptosis and exhibits cytotoxic activity on A549 cells, with an IC50 value of 91.35 μM [1].

Antitumor agent-100 hydrochloride (compound A6), serving as both an apoptosis inducer and molecular glue, exhibits superior anti-tumor activity [1].

Antitumor agent-60 is a potent antitumor agent that targets the RAS-RAF signaling pathway and binds to CRAF (Kd: 721.3 nM). antitumor agent-60 increases p53 and ROS levels in cancer cells, resulting in oval and irregular nuclei. antitumor agent-60 is sufficient to block the cell cycle in G2/M phase and induce apoptosis. Antitumor agent-60 is sufficient to block the cell cycle in G2/M phase and induce apoptosis. In the A549 tumor transplantation model, Antitumor agent-60 has the ability to inhibit tumor growth.

Antitumor agent-55 (compound 5q) is a potent antitumour agent that effectively inhibits PC3 (IC50: 0.91 μM). antitumor agent-55 blocks the G1/S phase of the PC3 cell cycle, induces apoptosis, inhibits cell migration and prevents the formation of PC3.

Antitumor agent-66 (Compound 4) is a derivative of (-)-cleistenolide, showcasing potential as a research tool for cancer diseases [1].

Antitumor Agent-71 is an antitumor compound that exhibits an inhibitory effect on tubulin aggregation. antitumor Agent-71 possesses an anti-proliferative effect with IC50 values ranging from 3.98-15.70 μM against tumor cell lines.

Antitumor agent-83 acts as a BAX pro-apoptotic protein activator, significantly inhibiting tumor cell proliferation and mediating cell apoptosis through BAX's conformational activation. It also impedes the A549 cell cycle, demonstrating robust metabolic stability and an in vitro CYPs spectrum.

Antitumor Agent-84, a G-quadruplex (G4)-ligand, stabilizes various G4-DNA structures, demonstrating highly effective antitumor properties.

Antitumor agent-46 is an anti-tumor agent. Antitumor agent-46 demonstrates markedly higher antiproliferative activity on MCF-7 cells with an IC 50 value of 2.08 µM .

Antitumor agent-47 is a silibinin derivative with an antitumor activity. Antitumor agent-47 shows cytotoxic activity against NCI-H1299 and HT29 cells with IC 50 values of 8.07 µM and 6.27 µM, respectively .

Antitumor agent-86 (compound 5a) demonstrates efficacy against MCF-7 breast cancer cells, manifesting an inhibitory concentration (IC 50) of 2.62 µM. It promotes apoptosis and cell cycle arrest, exhibiting antineoplastic effects through the disruption of RAS/PI3K/Akt/JNK signaling pathways [1].

Antitumor agent-77 inhibits the growth and migration of cancer cells and has anticancer effects. antitumor agent-77 inhibits GPx-4 and enhances COX2-induced iron sagging. antitumor agent-77 activates the intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) in tumor cells and prevents tumor cell epithelialization. Antitumor agent-77 activates the tumour cell intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and blocks the epithelial mesenchymal transition (EMT) process.

Antitumor agent-58 is an antitumour agent that effectively inhibits colony formation and cell migration in MGC-803 cells and induces mitochondrial dysfunction in MGC-803 cells. Antitumor agent-58 exhibited potent inhibitory activity against tumour growth in xenograft models carrying MGC-803 cells.

Antitumor agent-44 (Compound 5n) elicits potent antitumor effects by inducing disruption of mitochondrial homeostasis, cell cycle arrest, and apoptosis in human adenocarcinoma cells. Moreover, Antitumor agent-44 demonstrates significant anti-tumor activity in a lung cancer cell xenograft mice model [1].

Antitumor agent-97 (compound 42), an anticancer agent, effectively inhibits proliferation and autophagy in MGC 803 cells, induces apoptosis, and enhances ROS accumulation, proving useful in cancer research [1].

Antitumor Agent-113 exhibits cytotoxicity in A549 cells, with an IC50 of 46.60 μM, and induces apoptosis, making it applicable for research in non-small cell lung cancer [1].

Antitumor agent-96 (Compound D34) is a potent MRE11 inhibitor that down-regulates the homologous recombination (HR) pathway by binding to and suppressing the endonuclease functions of MRE11, thereby inducing apoptosis in CM cells [1].

Antitumor Agent-104 (Compound 9) serves as an antineoplastic by impeding DNA repair mechanisms in tumor cells, primarily through the inhibition of PARP1 enzyme activity and reduction of PAR protein levels. Additionally, it suppresses CDK12 expression [1].

Antitumor Agent-114, a potent STING (stimulator of interferon genes) agonist, activates immune responses and diminishes tumor size in mouse breast cancer models, demonstrating potential applications in immunity and cancer research [1].

Antitumor Agent-110 (Compound 13), an imidazotetrazine anticancer agent, exhibits excellent permeability. It halts the cell cycle at the G2/M phase and induces apoptosis [1].

Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects. It impedes the cell cycle at the G0/G1 phase and induces apoptosis [1].

Antitumor agent-115 (SS-12) is a potent anti-tumor compound, exhibiting an IC50 range of 0.34 μM-24.14 μM against the 4T1 mouse breast cancer cell line. It impedes the cell cycle, diminishes mitochondrial membrane potential, and triggers apoptosis in these cells, with an IC50 for cell viability spanning 8-25 μmol/L. This compound is applicable in breast cancer research [1].

Antitumor agent-54 (Compound C11) is a 14-3-3η protein inhibitor (KD: 35 μM). antitumor agent-54 inhibits several typical human hepatocellular carcinoma cell lines. antitumor agent-54 blocks the cell cycle in the G1-S phase and induces apoptosis, showing good metabolic stability. It exhibits good metabolic stability.

Antitumor agent-37 exhibits potent anti-proliferative and anti-metastatic effects. antitumor agent-37 induces severe DNA damage, leading to high expression of γ-H2AX and p53. antitumor agent-37 induces apoptosis by exploiting the mitochondrial apoptosis pathway Bcl-2/Bax/caspase3. Antitumor agent-37 inhibits PD-L1 expression, increases CD3+ and CD8+ T-infiltrating cells in tumour tissue and significantly improves the immune response.

Antitumor agent-75 is a novel and potent antitumor agent. antitumor agent-75 has cytotoxic effects on cancer and normal human cell lines. antitumor agent-75 in combination with antitumor agent-74 exhibits a highly selective cytotoxic effect (IC50: 2.8 μM) against human lung adenocarcinoma (cell line A549). Antitumor agent-75 can be used in cancer research.

Antitumor agent-65 (Compound 5) is an analogue/derivative of (-)-cleistenolide. Antitumor agent-65 has potential in cancer research.

Antitumor Agent-82 is a potent anti-tumor compound that exhibits anti-proliferative activity and induces cell autophagy through the ATG5/ATG7 signaling pathway.

Antitumor agent-36 exhibits strong anti-proliferative and anti-metastasis capabilities, causing significant DNA damage that results in elevated levels of γ-H2AX and p53. It promotes tumor cell apoptosis via the mitochondrial apoptotic pathway involving Bcl-2/Bax/caspase3 and enhances immune response by inhibiting PD-L1 expression, thereby increasing CD3+ and CD8+ T cell infiltration in tumor tissues [1].

Antitumor agent-61 (Compound 9b), an Irinotecan (Ir) derivative, demonstrates potent anticancer activity, as evidenced by its IC50 values ranging from 0.92 to 3.23 μM against six human cancer cell lines: SK-OV-3, SK-OV-3/CDDP, U2OS, MCF-7, A549, and MG-63. It specifically induces apoptosis in SK-OV-3 cells via mitochondrial pathways [1].

Antitumor Agent-92, an Icaritin derivative, induces G0/G1 phase cell cycle arrest and promotes apoptosis. This compound shows promise for hepatocellular carcinoma (HCC) research [1].

Antitumor Agent-73, a derivative of Diosgenin, both impedes STAT3 signaling and exogenously stimulates Pdia3/ERp57. This compound demonstrates significant antineoplastic efficacy, exhibiting potency against diverse cancer cell lines that ranges from 7.9 to 341.7 times that of Diosgenin [1].

Antitumor agent-43 (Compound 4B) is a potent antitumor agent that induces cell cycle arrest at G2/M phase. Antitumor agent-43 has an IC 50 of 0.5 μM for T-24 cells [1].